NCT06484803

Brief Summary

A major gap remains in understanding the neurobehavioral mechanism of individuals' variability in the dynamic process of responding to traumatic events. To address this gap, the proposed study is focused on two dominant survival processes: acute stress response and motivational behavior. Investigating the involvement of these processes in long-term recovery from a documented traumatic event, our study extends a prior longitudinal investigation in our lab that systematically assessed the neurobehavioral factors contributing to the development of PTSD.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 14, 2021

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

June 26, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 3, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

July 3, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

June 26, 2024

Last Update Submit

June 26, 2024

Conditions

Keywords

Trauma

Outcome Measures

Primary Outcomes (4)

  • PTSD Clinical trajectories

    Change in PTSD symptoms measured by change in Clinician-Administered PTSD Scale. The Clinician-Administered PTSD Scale is used to assess PTSD diagnostic status and symptom severity. We use both CAPS-V (according to DSM-4) and CAPS-5 (according to DSM-5) at 4 time points after exposure (1mo, 6mo, 14mo, \~60mo).

    Approximately 6 years

  • Change in PTSD symptoms following the October 7th, 2023 events

    Measured by the PTSD Checklist (PCL-5), a self-report measure (20 items) assessing the severity of PTSD symptoms, reflecting the diagnostic criteria of DSM-5. The PCL-5 total score can range from 0-80; with higher scores reflecting greater severity.

    Half an hour

  • Change in anxiety symptoms following the October 7th, 2023 events

    Measured by the Beck Anxiety Inventory (BAI), a self-reported measure (21 items) of concurrent anxiety symptoms.

    Half an hour

  • Change in depressive symptoms following the October 7th, 2023 events

    Measured by the Beck Depression Inventory (BDI), a self-reported measure (21 items) of depression symptoms and intensity, which was proven to be a good predictor of chronic PTSD at one week and one month after trauma.

    Half an hour

Secondary Outcomes (3)

  • Neural response to acute stress induction and PTSD resilience

    4 hours

  • Neural measures of reward and punishment and PTSD resilience

    4 hours

  • Neurobehavioral Measures of Approach-Avoidance Conflict Related to PTSD Resilience

    4 hours

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult civilians admitted to Tel-Aviv Sourasky Medical Center's Emergency Room (ER), following a potentially traumatic incident.

You may qualify if:

  • Participated in the initial study after an exposure to a traumatic event.
  • Age:18 - 70 years.
  • Able to read and comprehend Hebrew.

You may not qualify if:

  • Individuals who can't perform an MRI due to safety reasons (e.g. irremovable metals in their body) or claustrophobia.
  • Individuals with a diagnosis of substance abuse, psychotic or bipolar I disorder.
  • Individuals with documented head trauma with coma exceeding 30 minutes or with known neurological deficit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sourasky Medical Center

Tel Aviv, Israel

Location

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticWounds and Injuries

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2024

First Posted

July 3, 2024

Study Start

October 14, 2021

Primary Completion

September 30, 2024

Study Completion

September 30, 2024

Last Updated

July 3, 2024

Record last verified: 2024-06

Locations